A large randomised trial conducted across several African sites has found no clear evidence that starting empirical tuberculosis treatment reduces deaths among hospitalised infants living with HIV who have severe pneumonia. The study, known as EMPIRICAL, compared treatment strategies in a population where both infections are common and where early deaths remain a serious concern.

The trial was designed as a multicentre, randomised, open-label, 2×2 factorial superiority study. Its main comparison pitted empirical tuberculosis treatment, often abbreviated eTB-T, against a guided strategy in which treatment decisions followed diagnostic findings. A second comparison tested empirical valganciclovir, an antiviral drug, which was analysed separately. The valganciclovir arm produced a different result from the tuberculosis comparison on mortality.

The primary outcome was all-cause mortality among infants with HIV-associated pneumonia. Researchers did not find evidence that eTB-T produced a superior reduction in deaths compared with the guided approach. That finding challenges the assumption that presumptive tuberculosis treatment would automatically save more young lives in this setting.

The authors point to an important complication in interpreting the results. Many infants who were not assigned to empirical tuberculosis treatment went on to start tuberculosis therapy later during follow-up. That late treatment may have narrowed the differences between the two strategies, making it harder to see any real benefit. As a result, the trial leaves open whether a true mortality difference was missed or whether none exists.

For clinicians treating sick infants in high-burden regions, the findings underline how difficult it is to decide quickly between presumptive and diagnosis-guided care. The researchers' results add to the evidence base that will shape how guidelines weigh early tuberculosis treatment against more targeted approaches for HIV-exposed children with pneumonia.

Credit. Based on reporting for The Lancet. Is this your work? Write to us.

51Views

Jenna Mercer

Author

World News Correspondent

Jenna Mercer covers public affairs, politics, business, culture and daily news for Science Official. The role focuses on verification, context, and clear explanations for readers.